• How can QC teams detect and quantify raw material and intermediate variability before it impacts critical quality attributes of the final product
• What analytical controls are most effective for monitoring variability introduced during synthesis, conjugation, and purification
• How should acceptance criteria for raw materials and intermediates evolve as oligonucleotide and peptide programs move from early development to GMP manufacture
• What challenges exist in establishing stability indicating methods that are sensitive to upstream variability
• How can QC functions better integrate with manufacturing and supply teams to prevent variability driven deviations and batch failures

* Agenda subject to change